Global Cardiovascular Drugs Industry 2012-2017: Trend, Profit, and Forecast Analysis, July 2012
The global cardiovascular drugs industry sustained modest growth over the past five years and is anticipated to continue the same over 2012-2017 and reach an estimated $174.8 billion by 2017. Lucintel, a leading global management consulting and market research firm, has analyzed the global cardiovascular drugs industry and offers its findings in its research report, “Global Cardiovascular Drugs Industry 2012-2017: Trend, Profit, and Forecast Analysis.”
The industry is consolidated and affected by government regulations in different regions and countries. The global market is geographically segmented into North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW). During 2006-2011, APAC led the industry in growth and is expected to retain that position through 2017because of economic expansion, increased personal income, improved public healthcare, and longer life expectancies. Currently, North American dominates the industry. China and India are the fastest-growing cardiovascular drugs markets.
Lucintel has identified increasing regulatory interference, increasing export barriers, and shift toward lower-price generic drugs as challenges. Increasing healthcare expenditures and awareness, advances in medical technologies, and rising per capita income are industry growth stimulators.
Increase in middle class population, changing demographic profile, increase in medical insurance coverage, growing economy, and rising GDP per capita are expected to drive demand for cardiovascular drugs in APAC, providing opportunities to industry players.
The report includes manufacturers and distributors of cardiovascular drugs. This market report is an indispensable reference guide for materials suppliers, product manufacturers, investors, executives, distributors, and others that operate in this market. For business, investment, and strategic decisions, the timely, useful information in this market report can help fulfill these core needs.
Lucintel’s research report provides recent industry scope and overview, global macroeconomic overview, relative market attractiveness by region, annual industry trends, emerging trends, and industry forecasts. In addition, the report presents a Porter's Five Forces Analysis, information about product launches and merger and acquisitions during last five years that determine regional and segment opportunities, competitive landscape, and profitability trend and analysis of major industry players. The key insights sections portray beneficial information about an industry segment's growth and regional growth trends.
This comprehensive guide from Lucintel provides readers with valuable information and the tools needed to successfully drive critical business decisions with a thorough understanding of the market’s potential. This report will save Lucintel clients hundreds of hours in personal research time on a global market and it offers significant benefits in expanding business opportunities throughout the global cardiovascular drugs industry. In a fast-paced ever-changing world, business leaders need every advantage available to them in a timely manner to drive change in the market and to stay ahead of their competition. This report provides business leaders with a keen advantage in this regard by making them aware of emerging trends and demand requirements on an annual basis.
The industry is consolidated and affected by government regulations in different regions and countries. The global market is geographically segmented into North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW). During 2006-2011, APAC led the industry in growth and is expected to retain that position through 2017because of economic expansion, increased personal income, improved public healthcare, and longer life expectancies. Currently, North American dominates the industry. China and India are the fastest-growing cardiovascular drugs markets.
Lucintel has identified increasing regulatory interference, increasing export barriers, and shift toward lower-price generic drugs as challenges. Increasing healthcare expenditures and awareness, advances in medical technologies, and rising per capita income are industry growth stimulators.
Increase in middle class population, changing demographic profile, increase in medical insurance coverage, growing economy, and rising GDP per capita are expected to drive demand for cardiovascular drugs in APAC, providing opportunities to industry players.
The report includes manufacturers and distributors of cardiovascular drugs. This market report is an indispensable reference guide for materials suppliers, product manufacturers, investors, executives, distributors, and others that operate in this market. For business, investment, and strategic decisions, the timely, useful information in this market report can help fulfill these core needs.
Lucintel’s research report provides recent industry scope and overview, global macroeconomic overview, relative market attractiveness by region, annual industry trends, emerging trends, and industry forecasts. In addition, the report presents a Porter's Five Forces Analysis, information about product launches and merger and acquisitions during last five years that determine regional and segment opportunities, competitive landscape, and profitability trend and analysis of major industry players. The key insights sections portray beneficial information about an industry segment's growth and regional growth trends.
This comprehensive guide from Lucintel provides readers with valuable information and the tools needed to successfully drive critical business decisions with a thorough understanding of the market’s potential. This report will save Lucintel clients hundreds of hours in personal research time on a global market and it offers significant benefits in expanding business opportunities throughout the global cardiovascular drugs industry. In a fast-paced ever-changing world, business leaders need every advantage available to them in a timely manner to drive change in the market and to stay ahead of their competition. This report provides business leaders with a keen advantage in this regard by making them aware of emerging trends and demand requirements on an annual basis.
1. EXECUTIVE SUMMARY
2. INDUSTRY DEFINITION AND SCOPE
3. INDUSTRY OVERVIEW
4. GLOBAL MACROECONOMIC OVERVIEW
5. INDUSTRY TRENDS
6.INDUSTRY FORECASTS
7. EMERGING TRENDS
8. CONCLUSIONS
2. INDUSTRY DEFINITION AND SCOPE
3. INDUSTRY OVERVIEW
4. GLOBAL MACROECONOMIC OVERVIEW
5. INDUSTRY TRENDS
6.INDUSTRY FORECASTS
7. EMERGING TRENDS
8. CONCLUSIONS
LIST OF FIGURES
Chapter 3. Industry Overview
Figure3.1 External forces shaping global cardiovascular drugs industry
Chapter 4. Global Macroeconomic Overview
Figure 4.1: Global GDP growth rate trend
Figure 4.2: Global inflation rate trend
Figure 4.3: Global population growth rate trend
Figure 4.4: Global unemployment rate trend
Figure 4.5: Regional GDP growth rate trend
Figure 4.6: Regional inflation rate trend
Figure 4.7: Regional population growth rate trend
Figure 4.8: Regional unemployment rate trend
Chapter 5. Industry Trends
Figure 5.1: Global cardiovascular drugs industry annual trend: 2006-11 ($ B)
Figure 5.2: Global cardiovascular drugs industry regional trend 2006-11($ B)
Figure 5.3: Global cardiovascular drugs industry regional trend: 2006-11 (%)
Figure 5.4; Global cardiovascular drugs industry segment trend: 2006-11 ($ B)
Figure 5.5: Global cardiovascular drugs industry segment trend: 2006-11 (%)
Figure 5.6: Global cardiovascular drugs industry quarterly trend: 2006-11 ($ B)
Figure 5.7: Global cardiovascular drugs industry profitability trend: 2006-11
Figure 5.8: Global cardiovascular drugs industry revenue per employee trend: 2006-11
Figure 5.9: Cost structure trend in global cardiovascular drugs industry: 2006-2011
Figure 5.10: Cost Structure Trend in North America cardiovascular drugs industry: 2006-2011
Figure 5.11 Cost structure trend in European cardiovascular drugs industry: 2006-2011
Figure 5.12 Cost structure trend in Asia Pacific cardiovascular drugs industry: 2006-2011
Figure 5.13 Top 5 companies v/s global cardiovascular drugs industry gross profit & net profit analysis 2011
Figure 5.14: Cash on hand for global cardiovascular drugs imaging industry 2006-11($B)
Figure 5.15: Cash on hand for global cardiovascular drugs imaging industry 2006-11(%)
Figure 5.16: Total assets for global cardiovascular drugs imaging industry 2006-11 ($B)
Figure 5.17: Total assets for global cardiovascular drugs imaging industry 2006-11 (%)
Figure 5.18: Total debt for global cardiovascular drugs imaging industry 2006-11 ($ B)
Figure 5.19: Total debt for global cardiovascular drugs imaging industry 2006-11 (%)
Figure 5.20: Industry shares of top players in cardiovascular drugs industry in 2006
Figure 5.21: Industry shares of top players in global cardiovascular drugs industry in 2011
Figure 5.22: Global cardiovascular drugs industry market share analysis 2006
Figure 5.23: Global cardiovascular drugs industry market share analysis 2011
Chapter 6. Industry Forecasts
Figure 6.1: Global cardiovascular drugs industry annual forecast 2012-17 ($ B)
Figure 6.2: Global cardiovascular drugs industry quarterly forecast 2012-17 ($ B)
Figure 6.3: Global GDP growth rate forecast
Figure 6.4: Global inflation rate forecast
Figure 6.5: Global population growth rate forecast
Figure 6.6: Global unemployment rate forecast
Figure 6.7: Regional GDP growth rate forecast
Figure 6.8: Regional inflation rate forecast
Figure 6.9: Regional population growth rate forecast
Figure 6.10: Regional unemployment rate forecast
Figure 6.11: Global cardiovascular drugs industry regional forecast 2012-2017 ($ B)
Figure 6.12: Global cardiovascular drugs industry regional forecast 2012-2017 (%)
Figure 6.13: Global cardiovascular drugs industry segment forecast 2012-2017 ($ B)
Figure 6.12: Global cardiovascular drugs industry segment forecast 2012-2017 (%)
Chapter 7. Emerging Trends
Figure 7.1: Global cardiovascular drugs industry emerging trend
Figure 7.2: Global cardiovascular drugs industry opportunity by region
Figure 7.3: Global cardiovascular drugs industry opportunity by segment
Chapter 3. Industry Overview
Figure3.1 External forces shaping global cardiovascular drugs industry
Chapter 4. Global Macroeconomic Overview
Figure 4.1: Global GDP growth rate trend
Figure 4.2: Global inflation rate trend
Figure 4.3: Global population growth rate trend
Figure 4.4: Global unemployment rate trend
Figure 4.5: Regional GDP growth rate trend
Figure 4.6: Regional inflation rate trend
Figure 4.7: Regional population growth rate trend
Figure 4.8: Regional unemployment rate trend
Chapter 5. Industry Trends
Figure 5.1: Global cardiovascular drugs industry annual trend: 2006-11 ($ B)
Figure 5.2: Global cardiovascular drugs industry regional trend 2006-11($ B)
Figure 5.3: Global cardiovascular drugs industry regional trend: 2006-11 (%)
Figure 5.4; Global cardiovascular drugs industry segment trend: 2006-11 ($ B)
Figure 5.5: Global cardiovascular drugs industry segment trend: 2006-11 (%)
Figure 5.6: Global cardiovascular drugs industry quarterly trend: 2006-11 ($ B)
Figure 5.7: Global cardiovascular drugs industry profitability trend: 2006-11
Figure 5.8: Global cardiovascular drugs industry revenue per employee trend: 2006-11
Figure 5.9: Cost structure trend in global cardiovascular drugs industry: 2006-2011
Figure 5.10: Cost Structure Trend in North America cardiovascular drugs industry: 2006-2011
Figure 5.11 Cost structure trend in European cardiovascular drugs industry: 2006-2011
Figure 5.12 Cost structure trend in Asia Pacific cardiovascular drugs industry: 2006-2011
Figure 5.13 Top 5 companies v/s global cardiovascular drugs industry gross profit & net profit analysis 2011
Figure 5.14: Cash on hand for global cardiovascular drugs imaging industry 2006-11($B)
Figure 5.15: Cash on hand for global cardiovascular drugs imaging industry 2006-11(%)
Figure 5.16: Total assets for global cardiovascular drugs imaging industry 2006-11 ($B)
Figure 5.17: Total assets for global cardiovascular drugs imaging industry 2006-11 (%)
Figure 5.18: Total debt for global cardiovascular drugs imaging industry 2006-11 ($ B)
Figure 5.19: Total debt for global cardiovascular drugs imaging industry 2006-11 (%)
Figure 5.20: Industry shares of top players in cardiovascular drugs industry in 2006
Figure 5.21: Industry shares of top players in global cardiovascular drugs industry in 2011
Figure 5.22: Global cardiovascular drugs industry market share analysis 2006
Figure 5.23: Global cardiovascular drugs industry market share analysis 2011
Chapter 6. Industry Forecasts
Figure 6.1: Global cardiovascular drugs industry annual forecast 2012-17 ($ B)
Figure 6.2: Global cardiovascular drugs industry quarterly forecast 2012-17 ($ B)
Figure 6.3: Global GDP growth rate forecast
Figure 6.4: Global inflation rate forecast
Figure 6.5: Global population growth rate forecast
Figure 6.6: Global unemployment rate forecast
Figure 6.7: Regional GDP growth rate forecast
Figure 6.8: Regional inflation rate forecast
Figure 6.9: Regional population growth rate forecast
Figure 6.10: Regional unemployment rate forecast
Figure 6.11: Global cardiovascular drugs industry regional forecast 2012-2017 ($ B)
Figure 6.12: Global cardiovascular drugs industry regional forecast 2012-2017 (%)
Figure 6.13: Global cardiovascular drugs industry segment forecast 2012-2017 ($ B)
Figure 6.12: Global cardiovascular drugs industry segment forecast 2012-2017 (%)
Chapter 7. Emerging Trends
Figure 7.1: Global cardiovascular drugs industry emerging trend
Figure 7.2: Global cardiovascular drugs industry opportunity by region
Figure 7.3: Global cardiovascular drugs industry opportunity by segment
LIST OF TABLES
Chapter 3. Industry Overview
Table 3.1: Global cardiovascular drugs industry parameters 2011
Table 3.2: Relative Industry attractiveness by region
Chapter 5. Industry Trends
Table 5.1: Global cardiovascular drugs industry regional growth rate
Table 5.2: Global cardiovascular drugs industry segment growth rate
Table 5.3: Percentage change in cost structure
Table 5.4: Percentage change in cash on hand
Table 5.5: Percentage change in total assets
Table 5.6: Percentage change in total debt
Table 5.7: Key companies by highest revenue growth
Table 5.8: Key companies by lowest revenue growth
Chapter 6. Industry Forecasts
Table 6.1: Regional growth rate
Table 6.2: Segment growth rate
Chapter 3. Industry Overview
Table 3.1: Global cardiovascular drugs industry parameters 2011
Table 3.2: Relative Industry attractiveness by region
Chapter 5. Industry Trends
Table 5.1: Global cardiovascular drugs industry regional growth rate
Table 5.2: Global cardiovascular drugs industry segment growth rate
Table 5.3: Percentage change in cost structure
Table 5.4: Percentage change in cash on hand
Table 5.5: Percentage change in total assets
Table 5.6: Percentage change in total debt
Table 5.7: Key companies by highest revenue growth
Table 5.8: Key companies by lowest revenue growth
Chapter 6. Industry Forecasts
Table 6.1: Regional growth rate
Table 6.2: Segment growth rate
